Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, has announced the appointment of John Chiplin and Alan Dunton to its board of directors.
The company said the appointments add "skills and significant international experience" to its board and will support its global growth strategy.
"Dr Chiplin’s proven success sourcing global capital and Dr Dunton’s extensive experience in global drug development, commercialisation and pain management expertise will provide invaluable support to Regeneus in the further development and commercialisation of its Progenza and Sygenus platforms," said the company.
Dr Chiplin is managing director of Newstar Ventures and has significant operational, investment and transactions experience in the international life science and technology industries. Between 1995 and 2014, Dr Chiplin served as CEO at three publicly-listed software, biotechnology and cancer immunotherapy companies.
Dr Dunton is a senior pharmaceutical and biotechnology industry leader with over 35 years experience in senior company leadership roles. His experience spans leadership roles for large pharmaceutical research and development organisations to private biotechnology companies focused on prescriptive treatment and the development and commercialisation of over-the-counter drugs on a global and local scale.
“I am very pleased to welcome both John and Alan to the Board to support us through the Company’s next phase of growth and commercialisation," said Regeneus CEO Leo Lee.
"Their appointments bring a new mix of invaluable skills to support us through our next phase of growth, as we focus on commercialising our technology to address the huge and growing global pain market. With the deep experience John brings in raising capital internationally and Alan’s extensive experience in commercialising drugs on a global scale, I am confident of the significant value that will result from their strategic guidance and international connections.”
The company also said Roger Aston and John Martin will step down as non-executive chairman and non-executive director respectively.
"The Board would like to acknowledge the instrumental role played by John in the creation of Regeneus and his undisputed vision and drive to support the development of Progenza and Sygenus into important Company assets," said the company, also confirming the appointment of Barry Sechos as non-executive chairman.
“The Management and Board would like to express their heartfelt thanks to both Roger and John for their significant contribution over the years and acknowledge the key roles they have played in steering Regeneus through its growth,” said Mr Sechos.